Relvar Ellipta contains two medicines, fluticasone furoate and vilanterol. Relvar Ellipta is a long-acting beta2 agonist combined with an inhaled corticosteroid that is taken once daily for the treatment of asthma and COPD.
For further information on Relvar Ellipta including information on who is suitable for a Relvar Ellipta prescription, please see the Relvar Ellipta patient information leaflet (PIL). This link will take you to the electronic Medicines Compendium website which is a non-GSK website.
This guide can help you make the most of your treatment, but if you have any questions or concerns just ask your doctor, nurse or pharmacists and read the patient information leaflet provided with your medicine.
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.
Relvar and Ellipta are registered trademarks of the GlaxoSmithKline Group of Companies
M.C. Last updated: 07 December 2015. UK/RESP/0156/13(3)